Short communication: Effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia

AIDS Research and Human Retroviruses

Volumn 30, Issue 8, 2014, Pages 800-805

  Paranandi, Anu ^a   Asztalos, Bela F ^b   Mangili, Alexandra ^a,c   Kuvin, Jefferey ^a   Gerrior, Jul ^c   Sheehan, Heidi ^c   Skinner, Sally C ^c   Tang, Alice M ^c   Wanke, Christine A ^a,c  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; HEART PROTECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; BLOOD; COMPLICATION; FEMALE; HIV INFECTIONS; MALE; MIDDLE AGED;

ADULT; ANTI-RETROVIRAL AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; HIV INFECTIONS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84905496710     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0005     Document Type: Article

References (25)

1. Dube MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37(5):613-627.
2. Barter P, Kastelein J, Nunn A, et al.: High density lipo-proteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003;168:195-211.
3. Friis-Moller N, Weber R, Reiss P, et al.: Cardiovascular disease risk factors in HIV patients-association wit anti-retroviral therapy. Results from the DAD study. AIDS 2003;17(8):1179-1193.
4. Mangili A, Polak J, Skinner S, et al.: HIV infection and progression of carotid and coronary atherosclerosis: The CARE study. J Acquir Immune Defic Syndr 2011;58: 148-153.
5. Hellerstein MK, Wu K, McGrath M, et al.: Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: Relation to indices of cytokine production. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11(3): 258-270.
6. Thusgaard M, Christensen JH, Morn B, et al.: Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: A randomized, double-blind, placebo-controlled study. Scand J Infect Dis 2009;41(10):760-766.
7. Wohl DA, Tien HC, Busby M, et al.: Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hyper-triglyceridemia. Clin Infect Dis 2005;41(10):1498-1504.
8. Gerber JG, Kitch DW, Fichtenbaum CJ, et al.: Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: Results of ACTG A5186. J Acquir Immune Defic Syndr 2008;47(4): 459-466.
9. Woods MN, Wanke CA, Ling PR, et al.: Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV. Am J Clin Nutr 2009;90(6):1566-1578.
10. De Truchis P, Kirstetter M, Perier A, et al.: Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy. J Acquir Immune Defic Syndr 2007;44(3):278-285.
11. Asztalos BF, Tani M, and Schaefer EJ: Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011;22(3):176-185.
12. Asztalos BF, Batista M, Horvath KV, et al.: Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23:847-852.
13. Asztalos BF, Collins D, Cupples LA, Demissie S, et al.: Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Throm Vasc Biol 2005;25:2185-2191.
14. Asztalos BF, Horvath KV, McNamara JR, et al.: Comparing the effects of five different statins in the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002;164:361-369.
15. Asztalos BF, Le Maulf F, et al.: Comparison of the effects of high doses of rosuvastatin versus atorvastatin on subpopulations of high-density lipoproteins. Am J Cardiol 2007; 99:681-685.
16. Asztalos BF, Collins D, Horvath KV, et al.: Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 2008;57:77-83.
17. Asztalos B, Lefevre M, Wong L, et al.: Differential response to low-fat diet between low and normal HDL-cholesterol subjects. J Lipid Res 2000;41(3):321-328.
18. Asztalos BF, Roheim PS, Milani RL, et al.: Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20(12):2670-2676.
19. Carter VM, Woolley I, Jolley D, et al.: A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sex Health 2006;3(4):287-290.
20. McKenney JM and Sica D: Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Phar-macotherapy 2007;27(5):715-728.
21. Peters BS, Wierzbicki AS, Moyle G, et al.: The effect of 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: A randomized, placebo-controlled pilot trial. Clin Ther 2012;34(1):67-76.
22. Asztalos BF, Schaefer EJ, Horvath KV, et al.: Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis 2006;184(1):72-77.
23. Asztalos BF: High-density lipoprotein particles, coronary heart disease, and niacin. J Clin Lipidol 2010;4:405-410.
24. Asztalos BF, Schaefer EJ, Horvath KV, et al.: Role of LCAT in HDL remodeling: Investigation of LCAT deficiency states. J Lipid Res 2007;48:592-599.
25. Hage MP and Azar ST: Treating low high-density lipo-protein cholesterol: What is the evidence? Ther Adv En-docrinol Metab 2014;5(1):10-17.